CaRi-heart technology
Revolutionary new technology to assess the risk of a serious heart condition or heart attack – many years before anything happens.
Dr Jamshed Bomanji
Consultant in Nuclear Medicine, HCA Healthcare UK
Professor Jamshed Bomanji is a Consultant in Nuclear Medicine at HCA Healthcare UK and Clinical Lead and Head of the Institute of Nuclear Medicine at University College London Hospitals.
He is a pioneer in molecular imaging and radioligand therapies and has played a central role in advancing theranostics - combining targeted diagnosis and treatment - particularly in oncology.
Professor Bomanji is internationally recognised for translating nuclear medicine innovation into routine clinical practice.
In his session, Jamshed will introduce us to theranostics - a new generation of cancer treatment, along with real patient outcomes and the increasing use of theranostics in earlier stages of the cancer treatment pathway.
The emerging role of Theranostics & why it matters
Key takeaways
- Theranostics is highly targeted. It is used in specific tumours where it has the greatest benefit.
Theranostics*:
• ~£65,000 spend
• +0.42 QALYs gained
• ~£1,250 direct saving vs cabazitaxel
• 58% fewer skeletal complications
• 25% fewer severe toxicities
• 59% lower progression risk produce
- Theranostics should only be delivered in well-equipped centres, with the right supporting clinical infrastructure and appropriate multidisciplinary team
*Cost-effectiveness Analysis: Journal of the National Comprehensive Cancer Network 2023;21(1):43–50.